IPO Details
Bidding Dates
13 Nov 24 - 18 Nov 24
Price Range ₹
58 - 61
Total Equity
₹ 29.34Cr
Lot Size
2000
Exchange Status
NSE
IPO Doc
Subscription Rate
Non-Institutional Investor
0.00×
Qualified Institutional Buyers
0.00×
Employees
0.00×
Retail Investors
0.00×
Total subscription Rate
0.00×
IPO Timeline
Offer start
13 Nov 2024
Offer end
18 Nov 2024
Allotment
19 Nov 2024
Refund initiation
20 Nov 2024
Demat transfer
Invalid Date
Listing
22 Nov 2024
Offer start
13 Nov 2024
Offer end
18 Nov 2024
Allotment
19 Nov 2024
Refund initiation
20 Nov 2024
Demat transfer
Invalid Date
Listing
22 Nov 2024
About Company
Founded in May 2005, Onyx Biotec Limited is a pharmaceutical company specializing in the production of sterile water for injections. It operates as a contract manufacturer, offering a wide range of Dry Powder Injections and Dry Syrups for both domestic and international markets. The company operates two manufacturing units located in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II can produce 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift. Onyx Biotec's clientele includes notable pharmaceutical companies such as Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, and Reliance Life Sciences Limited, among others. As of May 31, 2024, Onyx Biotec served over 100 Indian and multinational pharmaceutical companies. The company is certified for management systems with ISO 9001:2015 and ISO 14001:2015 through ROHS Certification Private Limited. As of July 31, 2024, the company employed 175 individuals across various departments.
Year Founded
13-05-2005
Promotor Details
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 88.6 | 65.1 |
| Share Capital | 11803200 | 11803200 |
Offer to Public
48,10,000.00 Cr
Project Details
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals - 60.77cr
- Prepayment or repayment of all or a portion of certain loans availed by our Company - 120cr
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for - 12.41cr
Objectives
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use.Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections.Prepayment or repayment of all or a portion of certain loans availed by our Company.General Corporate Purposes.
Highlights
- With over a decade of expertise in sterile pharmaceutical manufacturing, the company has established a strong reputation among both Indian and multinational pharmaceutical companies.
- The company's two manufacturing units are located in Himachal Pradesh, a prominent pharmaceutical hub, providing access to skilled labor and cost-effective operations.
- Onyx Biotec holds ISO 9001:2015 certification for quality management systems and ISO 14001:2015 certification for environmental management systems, reflecting its commitment to high standards of quality and environmental care.
- The company serves a clientele of over 100 pharmaceutical companies, with a strong track record of repeat business from 35 clients, demonstrating customer trust and satisfaction.
- Onyx Biotec’s manufacturing facilities are WHO-GMP certified, and they undergo regular audits and inspections by clients and regulatory bodies to maintain compliance and ensure high production quality.
Challenges
- Both manufacturing facilities are located in Solan, Himachal Pradesh. This concentration means that any unfavorable changes in the regional business environment could significantly impact the company’s operations and overall prospects.
- The company could face contract losses if any manufacturing or quality control issues arise, or if it fails to deliver products on time. Such occurrences could have a detrimental effect on its reputation and business performance.
- Onyx Biotec relies heavily on domestic and international third-party suppliers for raw materials, with a significant portion of expenditures concentrated among the top five suppliers. Any disruption in supply from these sources could adversely affect its operations.
- The top 10 customers have contributed a large percentage of the company’s revenue in recent years. Losing any of these key customers or a decline in their business could negatively impact Onyx Biotec's financial stability.
- The company has experienced negative cash flows in recent years, potentially threatening its future growth and overall financial health. As of May 31, 2024, it had Rs 2.82 crore in unsecured loans and Rs 28.74 crore in secured loans. Any inability to service or repay these loans could adversely affect its operations and financial standing.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2024 | 7,413.58 | 1,332.22 | 303.16 | 303.16 | 2.2756 |
| 2022 | 3,683.84 | 590.16 | 335.29 | 335.29 | 2.8407 |
| 2023 | 5,872.36 | 590.16 | 303.16 | 303.16 | 2.2756 |
